These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 8510333)
1. [New protocols for myeloma chemotherapy plus IFN alpha]. Kitani T Rinsho Ketsueki; 1993 Apr; 34(4):455-9. PubMed ID: 8510333 [TBL] [Abstract][Full Text] [Related]
2. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]
3. [Recent therapy for refractory myeloma]. Togawa A Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332 [TBL] [Abstract][Full Text] [Related]
4. [Study on the therapy of multiple myelomas--initial induction therapy (MP, IFN alpha, steroid pulse) and maintenance therapy (VMP, MP continuous, VEP, MCNU)]. Tanaka H; Kawano M; Iwato K; Asaoku H; Tanabe O; Ishikawa H; Nobuyoshi M; Sakai A; Kuramoto A Rinsho Ketsueki; 1992 May; 33(5):655-61. PubMed ID: 1630017 [TBL] [Abstract][Full Text] [Related]
5. [Progress in the treatment of multiple myeloma]. Wada M; Mizoguchi H Gan To Kagaku Ryoho; 1997 Jul; 24(9):1079-88. PubMed ID: 9239160 [TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J; Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267 [TBL] [Abstract][Full Text] [Related]
7. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574 [TBL] [Abstract][Full Text] [Related]
8. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521 [TBL] [Abstract][Full Text] [Related]
9. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related]
10. Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in Japan. Wada M; Mizoguchi H; Kuriya SI; Taguchi H; Kawamura T; Maekawa I; Shimazaki C; Sato Y; Niho Y; Miyazaki T; Shibata A; Kitani T; Hamajima N; Ohno R Br J Haematol; 2000 Jun; 109(4):805-14. PubMed ID: 10929034 [TBL] [Abstract][Full Text] [Related]
11. [Combination chemotherapy of multiple myeloma]. Uzuka Y; Saito Y; Ito T Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1481-7. PubMed ID: 2389944 [TBL] [Abstract][Full Text] [Related]
12. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Tribalto M; Amadori S; Cudillo L; Caravita T; Del Poeta G; Meloni G; Avvisati G; Petrucci MT; Pulsoni A; Leone G; Sica S; Martelli M; Tabilio A; Fioritoni G; Majolino I; Mandelli F Haematologica; 2000 Jan; 85(1):52-8. PubMed ID: 10629592 [TBL] [Abstract][Full Text] [Related]
13. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma]. Luo SK; Li J; Hong WD; Zhao Y; Tong XZ Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805 [TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group. Imamura Y; Takagi T; Yawata Y; Nishinarita S; Kosaka M; Mikuni C; Takatsuki K; Sezaki T; Mori M; Tsuchiya J Int J Hematol; 1994 Feb; 59(2):113-23. PubMed ID: 8018904 [TBL] [Abstract][Full Text] [Related]
15. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD). Adam Z; Elbl L; Vorlicek J; Hájek R; Hájek D; Hejlová N; Králová E; Novotná H Acta Med Austriaca; 1994; 21(4):111-5. PubMed ID: 7871966 [TBL] [Abstract][Full Text] [Related]
16. All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma. Musto P; Sajeva MR; Sanpaolo G; D'Arena G; Scalzulli PR; Carotenuto M Haematologica; 1997; 82(3):354-6. PubMed ID: 9234591 [TBL] [Abstract][Full Text] [Related]
17. [Clinical trial of alpha-interferon (human lymphoblastoid interferon) in combination with VCAP chemotherapy in multiple myeloma]. Umeda M; Shirai T; Tsukahara T; Kaneko H; Yamauchi M; Arai N; Kosuge T; Kato M; Shikoshi K; Anno S Rinsho Ketsueki; 1991 Jun; 32(6):669-74. PubMed ID: 1890744 [TBL] [Abstract][Full Text] [Related]
18. [Clinical trial of a combination of human lymphoblastoid interferon (HLBI), melphalan and prednisolone (HLBI-MP) in multiple myeloma]. Hara M; Nakamura T; Fujii Y Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1338-41. PubMed ID: 3579331 [TBL] [Abstract][Full Text] [Related]
19. [Autologous transplantation of peripheral hematopoietic cells and subsequent maintenance therapy with interferon alpha or interferon alpha and dexamethasone in patients with multiple myeloma--results from the 4W randomized clinical trial of the Czech Myeloma Group]. Krejcí M; Hájek R; Scudla V; Bacovský J; Indrák K; Faber E; Koza V; Schützová M; Kuca B; Sumná E; Franková H; Lehanka F; Gumulec J; Stavarová Y; Rezek Z; Praskac P; Cahová S; Vránová M; Veprek K; Januska J; Kessler P; Pozdĕnová V; Walterová L; Stefánek I; Hausdorf P; Meluzínová I; Novosadová L; Lenícková S; Dusek L; Syobodník A; Králová E; Adam Z; Mayer J; Vorlícek J Vnitr Lek; 2001 Sep; 47 Suppl 1():40-7. PubMed ID: 11693062 [TBL] [Abstract][Full Text] [Related]
20. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. Dadacaridou M; Papanicolaou X; Maltesas D; Megalakaki C; Patos P; Panteli K; Repousis P; Mitsouli-Mentzikof C J BUON; 2007; 12(1):41-4. PubMed ID: 17436400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]